文献速递前列腺癌

前列腺特异性抗原标准诊断非转移性前列腺癌局灶高强度聚焦超声治疗后癌症控制失败

Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
PubMed 文献 · J Urol · 2020-01-13

该研究基于598例接受局灶高强度聚焦超声治疗的前列腺癌患者的前瞻性国家数据库,评估前列腺特异性抗原(PSA)标准诊断治疗失败的价值。结果显示,12个月时PSA最低值+1.0 ng/ml、24和36个月时+1.5 ng/ml具有100%敏感性和96.1%至100%阴性预测值,可能用于筛选需要磁共振成像和活检的患者。

要点

  • 局灶高强度聚焦超声治疗后,12个月PSA最低值+1.0 ng/ml和24-36个月+1.5 ng/ml具有高敏感性和阴性预测值。
  • PSA最低值+1.0 ng/ml在不同时间点敏感性27.3%-100%,特异性39.4%-85.6%。
  • PSA最低值+1.5 ng/ml敏感性18.2%-100%,特异性60.6%-91.8%。

核心结论

  • 局灶高强度聚焦超声治疗后,12个月PSA最低值+1.0 ng/ml和24-36个月+1.5 ng/ml可能用于筛选需要磁共振成像和活检的患者。

研究设计与样本

  • 随访包括第一年每3个月临床 visits 和PSA检测,之后每6-12个月PSA检测,对磁共振成像怀疑复发者进行活检。
  • 治疗失败定义为任何二次治疗、活检Gleason 3+4或更高疾病无进一步治疗、转移和/或前列腺癌相关死亡。

主要发现

  • 中位年龄65岁(IQR 60-71),中位Gleason评分7(范围6-9),80%病例为Gleason 3+4或更高。
  • 522/596例(88%)肿瘤放射学分期为T1c-T2c,74例(12.4%)为T3a/b。
  • 失败病例基线中位PSA为7.80 ng/ml(IQR 5.96-10.45),无失败病例为6.77 ng/ml(IQR 2.65-9.71)。
  • 12个月时PSA最低值+1.0 ng/ml和24、36个月时+1.5 ng/ml具有100%敏感性和96.1%至100%阴性预测值。

关键数值与推荐

  • PSA最低值+1.0 ng/ml在3年内的不同评估时间点敏感性27.3%至100%,特异性39.4%至85.6%。
  • PSA最低值+1.5 ng/ml敏感性18.2%至100%,特异性60.6%至91.8%。
  • PSA最低值+2.0 ng/ml敏感性和特异性范围与+1.5 ng/ml相似。

临床怎么用

  • 局灶高强度聚焦超声治疗后,12个月PSA最低值+1.0 ng/ml和24-36个月+1.5 ng/ml可用于筛选需要磁共振成像和活检的患者。
  • 这些数据需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We determined whether prostate specific antigen criteria after focal high intensity focused ultrasound to treat prostate cancer could diagnose treatment failure. MATERIALS AND METHODS: A total of 598 patients in a prospectively maintained national database underwent focal high intensity focused ultrasound with a Sonablate® 500 device from March 2007 to November 2016. Followup consisted of 3-month clinic visits and prostate specific antigen testing in year 1 with prostate specific antigen measurement every 6 to 12 months and multiparametric magnetic resonance imaging with biopsy for magnetic resonance imaging suspicious for recurrence. Treatment failure was considered any secondary treatment, tumor recurrence with Gleason 3 + 4 or greater disease on prostate biopsy without further treatment or metastasis and/or prostate cancer related mortality. To diagnose failure we evaluated a series of nadir + x thresholds with x values of 0.1 to 2.0 ng/ml. RESULTS: Median patient age was 65 years (IQR 60-71) and the median Gleason score was 7 (range 6-9). Gleason 3 + 4 or greater disease was present in 80% of cases. Tumors were radiologically staged as T1c-T2c in 522 of the 596 patients (88%) and as T3a/b in 74 (12.4%). Baseline median prostate specific antigen was 7.80 ng/ml (IQR 5.96-10.45) in failed cases and 6.77 ng/ml (IQR 2.65-9.71) in cases without failure. Optimal performance according to the Youden index to indicate the most appropriate nadir + x at all analyzed time points at 3-month intervals showed that nadir + 1.0 ng/ml would have 27.3% to 100% sensitivity and 39.4% to 85.6% specificity depending on the time of evaluation in the first 3 years. Nadir + 1.5 ng/ml showed 18.2% to 100% sensitivity and 60.6% to 91.8% specificity with nadir + 2.0 ng/ml leading to similar sensitivity and specificity ranges. Nadir + 1.0 ng/ml at 12 months and nadir + 1.5 ng/ml at 24 and 36 months had 100% sensitivity and 96.1% to 100% negative predictive value. CONCLUSIONS: Following focal high intensity focused ultrasound a prostate specific antigen nadir of 1.0 ng/ml at 12 months and 1.5 ng/ml at 24 to 36 months might be used to triage men requiring magnetic resonance imaging and biopsy. These data need prospective validation.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Huber PM, Afzal N, Arya M, et al. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol. 2020. PMID: 31928408. doi:10.1097/JU.0000000000000747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。